Literature DB >> 1336950

Susceptibility of Rickettsia conorii, R. rickettsii, and Coxiella burnetii to PD 127,391, PD 131,628, pefloxacin, ofloxacin, and ciprofloxacin.

N Jabarit-Aldighieri1, H Torres, D Raoult.   

Abstract

Plaque formation and dye uptake assays were used to measure the MICs of PD 127,391 and PD 131,628 against Rickettsia species. The MICs of PD 127,391 were 0.25 microgram/ml for Rickettsia rickettsii and 0.125 to 0.25 microgram/ml for Rickettsia conorii. The MICs of PD 131,628 were 0.25 to 0.5 microgram/ml for R. rickettsii and 0.5 microgram/ml for R. conorii. As determined by the shell vial technique, 15 strains of Coxiella burnetii were susceptible to PD 127,391 and PD 131,628 (MIC, < or = 1 microgram/ml), while one strain of C. burnetii (MP10) was of intermediate susceptibility.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1336950      PMCID: PMC284367          DOI: 10.1128/AAC.36.11.2529

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Tetracycline in the treatment of "Q" fever.

Authors:  O W POWELL; K P KENNEDY; M McIVER; H SILVERSTONE
Journal:  Australas Ann Med       Date:  1962-08

2.  Shell-vial assay: evaluation of a new technique for determining antibiotic susceptibility, tested in 13 isolates of Coxiella burnetii.

Authors:  D Raoult; H Torres; M Drancourt
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

Review 3.  Antimicrobial therapy of rickettsial diseases.

Authors:  D Raoult; M Drancourt
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

4.  Fatal cases of Rocky Mountain spotted fever in the United States, 1981-1988.

Authors:  D B Fishbein; M G Frontini; R Giles; L L Vernon
Journal:  Ann N Y Acad Sci       Date:  1990       Impact factor: 5.691

5.  The role of lipopolysaccharides in the virulence of Coxiella burnetii.

Authors:  T Hackstadt
Journal:  Ann N Y Acad Sci       Date:  1990       Impact factor: 5.691

6.  Incidence, clinical observations and risk factors in the severe form of Mediterranean spotted fever among patients admitted to hospital in Marseilles 1983-1984.

Authors:  D Raoult; P Zuchelli; P J Weiller; C Charrel; J L San Marco; H Gallais; P Casanova
Journal:  J Infect       Date:  1986-03       Impact factor: 6.072

7.  Bactericidal effect of doxycycline associated with lysosomotropic agents on Coxiella burnetii in P388D1 cells.

Authors:  D Raoult; M Drancourt; G Vestris
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

8.  Successful treatment of Rocky Mountain 'spotless' fever.

Authors:  P G Ramsey; O W Press
Journal:  West J Med       Date:  1984-01

9.  Isolation of 16 strains of Coxiella burnetii from patients by using a sensitive centrifugation cell culture system and establishment of the strains in HEL cells.

Authors:  D Raoult; G Vestris; M Enea
Journal:  J Clin Microbiol       Date:  1990-11       Impact factor: 5.948

10.  In vitro susceptibilities of Coxiella burnetii, Rickettsia rickettsii, and Rickettsia conorii to the fluoroquinolone sparfloxacin.

Authors:  D Raoult; P Bres; M Drancourt; G Vestris
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

View more
  9 in total

Review 1.  From Q Fever to Coxiella burnetii Infection: a Paradigm Change.

Authors:  Carole Eldin; Cléa Mélenotte; Oleg Mediannikov; Eric Ghigo; Matthieu Million; Sophie Edouard; Jean-Louis Mege; Max Maurin; Didier Raoult
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

Review 2.  Treatment of Q fever.

Authors:  D Raoult
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

Review 3.  Tick-borne encephalopathies : epidemiology, diagnosis, treatment and prevention.

Authors:  Göran Günther; Mats Haglund
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

4.  In vitro susceptibility of Coxiella burnetii to linezolid in comparison with its susceptibilities to quinolones, doxycycline, and clarithromycin.

Authors:  A Gikas; I Spyridaki; E Scoulica; A Psaroulaki; Y Tselentis
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

5.  In vitro susceptibility of Coxiella burnetii to trovafloxacin in comparison with susceptibilities to pefloxacin, ciprofloxacin, ofloxacin, doxycycline, and clarithromycin.

Authors:  A Gikas; I Spyridaki; A Psaroulaki; D Kofterithis; Y Tselentis
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

6.  Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.

Authors:  Ioanna Spyridaki; Anna Psaroulaki; Iosif Vranakis; Yannis Tselentis; Achilleas Gikas
Journal:  Antimicrob Agents Chemother       Date:  2009-03-30       Impact factor: 5.191

7.  In vitro susceptibilities of 27 rickettsiae to 13 antimicrobials.

Authors:  J M Rolain; M Maurin; G Vestris; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

8.  The microbiota changes of the brown dog tick, Rhipicephalus sanguineus under starvation stress.

Authors:  Liping An; Biswajit Bhowmick; Dejuan Liang; Penghui Suo; Chenghong Liao; Jianguo Zhao; Qian Han
Journal:  Front Physiol       Date:  2022-09-09       Impact factor: 4.755

Review 9.  Epidemiology, Clinical Aspects, Laboratory Diagnosis and Treatment of Rickettsial Diseases in the Mediterranean Area During COVID-19 Pandemic: A Review of the Literature.

Authors:  Andrea De Vito; Nicholas Geremia; Sabrina Maria Mameli; Vito Fiore; Pier Andrea Serra; Gaia Rocchitta; Susanna Nuvoli; Angela Spanu; Renato Lobrano; Antonio Cossu; Sergio Babudieri; Giordano Madeddu
Journal:  Mediterr J Hematol Infect Dis       Date:  2020-09-01       Impact factor: 2.576

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.